Magenta Therapeutics, Inc (MGTA)

Etorro trading 970x250
Magenta Therapeutics, Inc (MGTA) Logo

About Magenta Therapeutics, Inc

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to bring the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. The company is developing C100 and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent prophylaxis of graft-versus-host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate potential utility of MGTA-117 for conditioning of patients receiving one or more investigational lentiviral gene therapies; and clinical trial collaboration with bluebird bio, Inc. to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: 100 Technology Square, Cambridge, MA, United States, 02139

Magenta Therapeutics, Inc News and around…

Latest news about Magenta Therapeutics, Inc (MGTA) common stock and company :

66 Biggest Movers From Friday
23 May, 2022 FinancialContent

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 ...

76 Biggest Movers From Yesterday
19 May, 2022 FinancialContent

Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
18 May, 2022 FinancialContent

Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 15.2% to $0.22 during Wednesday's regular session. ...

Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial
16 May, 2022 FinancialContent

Magenta Therapeutics Inc(NASDAQ: MGTA)shared preliminary datafrom the Phase 1/2 dose-escalation trial of MGTA-117 ...

The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
16 May, 2022 FinancialContent

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks ...

After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)
16 May, 2022 Yahoo! Finance

The heavy selling pressure might have exhausted for Magenta Therapeutics, Inc. (MGTA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Magenta Therapeutics: Q1 Earnings Insights
16 May, 2022 FinancialContent

Magenta Therapeutics (NASDAQ:MGTA) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what ...

Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
16 May, 2022 FinancialContent

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today reported financial results for the first quarter ending March 31, 2022, early clinical observations from its MGTA-117 clinical trial and other recent program highlights.

First Week of November 18th Options Trading For Magenta Therapeutics (MGTA)
11 May, 2022 FinancialContent

Investors in Magenta Therapeutics Inc (MGTA) saw new options begin trading this week, for the November 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 191 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Here's Why We're Watching Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
10 May, 2022 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag
26 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Protagonist's Ulcerative ...

18 Stocks Moving in Tuesday's Pre-Market Session
26 Apr, 2022 FinancialContent

Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% ...

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
24 Apr, 2022 FinancialContent

Biotech stocks extended their loses in the week endingApril 22. The sector took cues from the broader market, which reacted to the ...

Stocks That Hit 52-Week Lows On Thursday
21 Apr, 2022 FinancialContent

On Thursday, 236 companies hit new 52-week lows. Intriguing Points From Today's 52-Week ...

Stocks That Hit 52-Week Lows On Wednesday
20 Apr, 2022 FinancialContent

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney ...

InvestorNewsBreaks – Magenta Therapeutics Inc. (NASDAQ: MGTA) Featured in Mizuho Securities Research Report
18 Apr, 2022 FinancialContent
Stem cell startup cuts staff by 14%
14 Apr, 2022 Yahoo! Finance

Magenta Therapeutics Inc. has cut its workforce by 14% as it scales back work on a drug for blood cancers and sickle-cell disease.

Magenta Therapeutics Trims R&D, Cuts Workforce
14 Apr, 2022 FinancialContent

Magenta Therapeutics Inc(NASDAQ: MGTA) is cutting 14% of staff and axing a planned dosing optimization trial for a stem cell ...

Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
14 Apr, 2022 FinancialContent

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced progress and encouraging early data in its MGTA-117 Phase 1/2 targeted conditioning clinical trial and a prioritization of its operating plan to more narrowly focus its capital allocation on the MGTA-117 targeted conditioning program, the CD45-ADC (antibody-drug conjugate) IND-enabling activities and the MGTA-145 stem cell mobilization efforts in sickle cell disease.

Recap: Magenta Therapeutics Q4 Earnings
08 Mar, 2022 FinancialContent

Magenta Therapeutics (NASDAQ:MGTA) reported its Q4 earnings results on Tuesday, March 8, 2022 at 08:00 AM. Here's what ...

Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights
08 Mar, 2022 FinancialContent

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today reported financial results for the fourth quarter and full-year ended December 31, 2021, and recent program highlights.

Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference
03 Mar, 2022 FinancialContent

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in a Cell Therapy Panel Discussion at the 42nd Annual Cowen Healthcare Conference, to be held virtually, on Wednesday, March 9th, 2022 at 9:10 a.m. ET.

How The Pieces Add Up: FDM Targets $78
11 Feb, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $77.94 per unit.

What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
07 Feb, 2022 Yahoo! Finance

A look at the shareholders of Magenta Therapeutics, Inc. ( NASDAQ:MGTA ) can tell us which group is most powerful...

Stocks That Hit 52-Week Lows On Friday
04 Feb, 2022 FinancialContent

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta ...

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
18 Jan, 2022 Yahoo! Finance

Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland, CEO of GeneDx and former CCO of Invitae, to join Sema4 as Co-CEO, alongside Eric Schadt, PhD, and become a member of Sema4’s Board of Directors Director Jason Ryan, former CFO of Foundation Medicine, to assume role of Executive Chair of Sema4’s Board o

Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
10 Jan, 2022 FinancialContent

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today highlighted progress across its portfolio of targeted conditioning and stem cell mobilization programs and set out its milestone expectations for both clinical and preclinical data in 2022. These updates will also be discussed during a webcast presentation at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 9:45 a.m. EST.

58 Biggest Movers From Yesterday
07 Jan, 2022 FinancialContent

Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of ...

12 Health Care Stocks Moving In Thursday's Intraday Session
06 Jan, 2022 FinancialContent

Gainers Eargo (NASDAQ:EAR) stock increased by 50.0% to $6.84 during Thursday's regular session. The current volume ...

Thursday's ETF with Unusual Volume: VTWV
06 Jan, 2022 FinancialContent

The Vanguard Russell 2000 Value ETF is seeing unusually high volume in afternoon trading Thursday, with over 294,000 shares traded versus three month average volume of about 43,000. Shares of VTWV were up about 1.1% on the day.

Magenta Therapeutics, Inc (MGTA) is a NASDAQ Common Stock listed in , ,

970x250